The combined ZYTIGA® and prednisone administration increases the overall survival rate in men with the metastatic castration-resistant prostate cancer in the early stages or in cases of the nonaggressive disease state (Munich, Germany)

Editorial article

For citations:

article E. The combined ZYTIGA® and prednisone administration increases the overall survival rate in men with the metastatic castration-resistant prostate cancer in the early stages or in cases of the nonaggressive disease state (Munich, Germany). Cancer Urology. 2016;12(2):100-101.

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Cancer Urology

For citations:

Cookies policy